Personal information

No personal information available

Activities

Collapse all

Works (8)

Guselkumab in Biologic-Naïve Patients with Active Psoriatic Arthritis in Russia: A Post Hoc Analysis of the DISCOVER-1 and -2 Randomized Clinical Trials

Rheumatology and Therapy
2024-12 | Journal article
DOI: 10.1007/s40744-024-00713-x
Contributors: Philip Mease; Tatiana Korotaeva; Pavel Shesternya; Muza Kokhan; Anton Rukavitsyn; Dmitry Vasilchenkov; Mohamed Sharaf; Frédéric Lavie; Atul Deodhar
Source: check_circle
Crossref

Sustained response to guselkumab regardless of baseline characteristics in patients with active psoriatic arthritis and inadequate response to TNF inhibitors: results from the phase 3b COSMOS clinical trial

RMD Open
2024-12 | Journal article
DOI: 10.1136/rmdopen-2024-004494
Contributors: Iain B McInnes; Philipp Sewerin; Mohamed Sharaf; Michela Efficace; Frédéric Lavie; Miriam Zimmermann; Laura C Coates
Source: check_circle
Crossref

Multi-domain effectiveness of guselkumab evaluated via composite indices through 1 year in patients with PsA and inadequate response to TNFi: post hoc analysis of COSMOS

Rheumatology
2024-10-22 | Journal article
DOI: 10.1093/rheumatology/keae586
Contributors: Laure Gossec; Xenofon Baraliakos; Daniel Aletaha; Mohamed Sharaf; Emmanouil Rampakakis; Frédéric Lavie; Clementina López-Medina; Carlo Selmi; Laura C Coates
Source: check_circle
Crossref

Improvement in patient-reported outcomes and work productivity following 3-year ustekinumab or tumour necrosis factor inhibitor treatment in patients with psoriatic arthritis: results from the PsABio real-world study.

Arthritis research & therapy
2023-06 | Journal article
DOI: 10.1186/s13075-023-03058-y
PMID: 37353788
PMC: PMC10288720
Contributors: Gossec L; Siebert S; Bergmans P; de Vlam K; Gremese E; Joven-Ibáñez B; Korotaeva TV; Lavie F; Noël W; Nurmohamed MT et al.
Source: Self-asserted source
Mohamed Sharaf via Europe PubMed Central

Response to treatment in psoriatic arthritis, the effect of age: analysis of patients receiving ustekinumab in the PsABio real-world study.

Arthritis research & therapy
2023-06 | Journal article
DOI: 10.1186/s13075-023-03078-8
PMID: 37296456
PMC: PMC10251537
Contributors: Gossec L; Theander E; Chakravarty SD; Bergmans P; Lavie F; Noël W; Sharaf M; Siebert S; Smolen JS
Source: Self-asserted source
Mohamed Sharaf via Europe PubMed Central

Gender-specific differences in patients with psoriatic arthritis receiving ustekinumab or tumour necrosis factor inhibitor: real-world data.

Rheumatology (Oxford, England)
2023-02 | Journal article
DOI: 10.1093/rheumatology/kead089
PMID: 36810788
Contributors: Van Kuijk AWR; Nurmohamed MT; Siebert S; Bergmans P; de Vlam K; Gremese E; Joven-Ibáñez B; Korotaeva TV; Lavie F; Sharaf M et al.
Source: Self-asserted source
Mohamed Sharaf via Europe PubMed Central

Long-term effectiveness and persistence of ustekinumab and TNF inhibitors in patients with psoriatic arthritis: final 3-year results from the PsABio real-world study.

Annals of the rheumatic diseases
2022-12 | Journal article
DOI: 10.1136/ard-2022-222879
PMID: 36600178
PMC: PMC10086293
Contributors: Gossec L; Siebert S; Bergmans P; de Vlam K; Gremese E; Joven-Ibáñez B; Korotaeva TV; Lavie F; Noël W; Nurmohamed MT et al.
Source: Self-asserted source
Mohamed Sharaf via Europe PubMed Central

PsABIOnd Study and eDaily Substudy Design: Long-Term Effectiveness and Safety of Guselkumab and IL-17 Inhibitors in Routine Clinical Practice in Patients with Psoriatic Arthritis.

Rheumatology and therapy
2022-12 | Journal article
DOI: 10.1007/s40744-022-00518-w
PMID: 36585602
PMC: PMC10011238
Contributors: Siebert S; Behrens F; Lubrano E; Martin N; Sharaf M; Contré C; Theander E; Queiro R; Zimmermann M; Gossec L
Source: Self-asserted source
Mohamed Sharaf via Europe PubMed Central
How many people are using ORCID?